ecrin-mdr-crcClinical2020Colorectal cancerColorectal CancerInterventionalhttps://newmdr.ecrin.org/Study/2691549China3ECRIN MDRRecruitingfalseThe safety, tolerability and preliminary efficacy of pd-l1 monoclonal antibody combined with lenalidomide in third-line post-treatment of patients with microsatellite stable advanced colorectal cancer: a phase I clinical studInterventions: single arm:Pd-l1 monoclonal antibody and lenalidomide Primary outcome(s): Security;Tolerance Study Design: Single arm2020-03-152691549ChiCTR2000030847